Company / Operating Income
X4 Pharmaceuticals, Inc Operating Income History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$107.5M
FY2025
5-year range
-$107.5M / -$29.1M
FY2021-FY2025
Trend
-22.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has declined for 5 consecutive years, from -$24M in FY2018 to -$108M in FY2025.
Based on SEC 10-K filings.
-$108M in FY2025.
Declined from -$60M to -$108M over the past 3 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- X4 Pharmaceuticals, Inc's operating income has declined for 5 consecutive years.
- In FY2025, operating income decreased 22.8% year-over-year.
- Peak operating income was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score -0.53 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$107.5M | -22.8% |
| FY2024 | -$87.6M | -46.3% |
| FY2022 | -$59.9M | -15.8% |
| FY2021 | -$51.7M | -77.8% |
| FY2020 | -$29.1M | -19.5% |
| FY2018 | -$24.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026